Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after a yearslong wait. Monday, Viatris and Amphastar Pharmaceuticals both said they have received the FDA’s ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

Viatris has seen its Fair Value Estimate nudge higher from $12.00 to $12.13 as analysts revise their assumptions for the company's future growth and market opportunities. This modest upward adjustment ...

Generic drug manufacturers are facing increasing pressure from drug distributors, pharmacy benefit managers, and Indian competitors, leading to downward trends in generic drug prices. Which firms are ...

Viatris Inc. (NASDAQ:VTRS) reported third-quarter 2024 total net sales of $3.74 billion. That’s down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational ...

Viatris faces declining revenues and increasing R&D, mitigated by aggressive divestitures aimed at operational streamlining and debt reduction. High long-term debt is a concern, but disciplined debt ...